{
  "abstract": "A man in his 20s presented with fever, night sweats and marked leucocytosis (94×109/L). Cervical lymph node biopsy confirmed peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). The disease was refractory to brentuximab vedotin plus cyclophosphamide, doxorubicin and prednisone, SMILE and pralatrexate. Subsequently, single-agent gemcitabine (1000 mg/m² on days 1, 8 and 15) induced complete remission, unconfirmed (CRu), after two cycles, enabling reduced-intensity allogeneic haematopoietic stem-cell transplantation from an HLA one-locus-mismatched related donor in the host-versus-graft direction. The patient remains in remission 36 months post-transplant. Throughout the course, serial leucocyte-to-lymphocyte ratio (LLR) measurements appeared to parallel disease activity, with elevation during refractory disease and normalisation in remission. This case suggests that single-agent gemcitabine may provide a feasible low-toxicity bridge to transplantation in selected refractory PTCL-NOS and that serial LLR measurements may represent a simple adjunctive marker of disease dynamics.",
  "authors": [
    {
      "affiliations": [
        "Hematology, Kansai Electric Power Hospital, Osaka, Osaka, Japan"
      ],
      "name": "Tomoya Kitagawa"
    },
    {
      "affiliations": [
        "Hematology, Kansai Electric Power Hospital, Osaka, Osaka, Japan"
      ],
      "name": "Kiyotaka Izumi"
    },
    {
      "affiliations": [
        "Hematology, Kansai Electric Power Hospital, Osaka, Osaka, Japan"
      ],
      "name": "Katsuhiro Io"
    }
  ],
  "title": "Single-agent gemcitabine enabling successful bridging to allogeneic haematopoietic stem-cell transplantation in refractory peripheral T-cell lymphoma, not otherwise specified",
  "uid": "b11ad358-b2e5-5492-aa6c-782d63ccf02a"
}